MA37506B1 - Utilisations thérapeutiques de protéines de facteur de croissance des fibroblastes 21 - Google Patents
Utilisations thérapeutiques de protéines de facteur de croissance des fibroblastes 21Info
- Publication number
- MA37506B1 MA37506B1 MA37506A MA37506A MA37506B1 MA 37506 B1 MA37506 B1 MA 37506B1 MA 37506 A MA37506 A MA 37506A MA 37506 A MA37506 A MA 37506A MA 37506 B1 MA37506 B1 MA 37506B1
- Authority
- MA
- Morocco
- Prior art keywords
- growth factor
- fibroblast growth
- therapeutic uses
- factor proteins
- proteins
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/18—Growth factors; Growth regulators
- A61K38/1825—Fibroblast growth factor [FGF]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
- A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Physical Education & Sports Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Chemical & Material Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Rheumatology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Zoology (AREA)
- Gastroenterology & Hepatology (AREA)
- Immunology (AREA)
- Epidemiology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Organic Chemistry (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Peptides Or Proteins (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
Abstract
La présente invention concerne des utilisations thérapeutiques de protéines de facteur de croissance des fibroblastes 21 (fgf21) humain.
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201261646974P | 2012-05-15 | 2012-05-15 | |
US201361786939P | 2013-03-15 | 2013-03-15 | |
PCT/US2013/040275 WO2013173158A1 (fr) | 2012-05-15 | 2013-05-09 | Utilisations thérapeutiques de protéines de facteur de croissance des fibroblastes 21 |
Publications (2)
Publication Number | Publication Date |
---|---|
MA37506A1 MA37506A1 (fr) | 2016-01-29 |
MA37506B1 true MA37506B1 (fr) | 2017-03-31 |
Family
ID=48483225
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
MA37506A MA37506B1 (fr) | 2012-05-15 | 2013-05-09 | Utilisations thérapeutiques de protéines de facteur de croissance des fibroblastes 21 |
Country Status (21)
Country | Link |
---|---|
US (1) | US20150141335A1 (fr) |
EP (1) | EP2852398A1 (fr) |
JP (1) | JP2015522539A (fr) |
KR (1) | KR20150002801A (fr) |
CN (1) | CN104302311A (fr) |
AU (1) | AU2013263188A1 (fr) |
BR (1) | BR112014028413A2 (fr) |
CA (1) | CA2869320A1 (fr) |
CL (1) | CL2014002846A1 (fr) |
CO (1) | CO7131381A2 (fr) |
EA (1) | EA201491856A1 (fr) |
HK (1) | HK1202800A1 (fr) |
IL (1) | IL235482A0 (fr) |
MA (1) | MA37506B1 (fr) |
MX (1) | MX2014013913A (fr) |
PE (1) | PE20142432A1 (fr) |
PH (1) | PH12014502537A1 (fr) |
SG (1) | SG11201407655TA (fr) |
TN (1) | TN2014000409A1 (fr) |
WO (1) | WO2013173158A1 (fr) |
ZA (1) | ZA201407532B (fr) |
Families Citing this family (17)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
KR102077721B1 (ko) | 2011-07-01 | 2020-02-14 | 엔지엠 바이오파마슈티컬스, 아이엔씨. | 대사성 장애 및 질환의 치료를 위한 조성물, 용도 및 방법 |
EP3798228A1 (fr) | 2012-11-28 | 2021-03-31 | NGM Biopharmaceuticals, Inc. | Compositions et procédés pour le traitement de troubles métaboliques et de maladies |
US9290557B2 (en) | 2012-11-28 | 2016-03-22 | Ngm Biopharmaceuticals, Inc. | Compositions comprising variants and fusions of FGF19 polypeptides |
US9273107B2 (en) | 2012-12-27 | 2016-03-01 | Ngm Biopharmaceuticals, Inc. | Uses and methods for modulating bile acid homeostasis and treatment of bile acid disorders and diseases |
ES2915851T3 (es) | 2012-12-27 | 2022-06-27 | Ngm Biopharmaceuticals Inc | Péptidos quiméricos de FGF19 para usar en el tratamiento de trastornos de ácidos biliares |
CA2927592C (fr) | 2013-10-28 | 2020-08-18 | Ngm Biopharmaceuticals, Inc. | Variants de fgf-19 pour le traitement d'un cancer ou d'une tumeur fgf-19-dependant |
EP3097122B9 (fr) | 2014-01-24 | 2020-11-11 | NGM Biopharmaceuticals, Inc. | Anticorps liant beta-klotho 2 et leurs procédés d'utilisation |
WO2015183890A2 (fr) | 2014-05-28 | 2015-12-03 | Ngm Biopharmaceuticals, Inc. | Méthodes et compositions pour le traitement de maladies et de troubles métaboliques |
US10456449B2 (en) | 2014-06-16 | 2019-10-29 | Ngm Biopharmaceuticals, Inc. | Methods and uses for modulating bile acid homeostasis and treatment of bile acid disorders and diseases |
WO2016039339A1 (fr) * | 2014-09-08 | 2016-03-17 | 国立大学法人大阪大学 | Agent de prévention ou traitement de la maladie démyélinisante |
IL251834B2 (en) | 2014-10-23 | 2023-09-01 | Ngm Biopharmaceuticals Inc | Pharmaceutical compositions containing peptide variants and methods of using them |
WO2016073855A1 (fr) | 2014-11-07 | 2016-05-12 | Ngm Biopharmaceuticals, Inc. | Procédés de traitement de troubles liés à l'acide biliaire et prédiction de la sensibilité clinique au traitement de troubles liés aux acides biliaires |
US10800843B2 (en) | 2015-07-29 | 2020-10-13 | Ngm Biopharmaceuticals, Inc. | Beta klotho-binding proteins |
CA3082794A1 (fr) | 2015-11-09 | 2017-05-18 | Ngm Biopharmaceuticals Inc. | Methodes de traitement de troubles associes aux acides biliaires |
EP3503882A4 (fr) | 2016-08-26 | 2020-07-29 | NGM Biopharmaceuticals, Inc. | Méthodes de traitement de cancers et de tumeurs à médiation assurée par le facteur de croissance des fibroblastes 19 |
CN108324928B (zh) * | 2018-03-05 | 2020-09-08 | 哈尔滨医科大学 | 重组人成纤维细胞生长因子-5在促骨折愈合中的应用 |
WO2021139744A1 (fr) | 2020-01-11 | 2021-07-15 | Beijing Ql Biopharmaceutical Co., Ltd. | Conjugués de protéines de fusion du glp-1 et du fgf21 |
Family Cites Families (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN104163864B (zh) * | 2007-03-30 | 2017-08-01 | Ambrx公司 | 经修饰fgf‑21多肽和其用途 |
AR087973A1 (es) * | 2011-10-04 | 2014-04-30 | Lilly Co Eli | Variantes del factor 21 del crecimiento de fibroblastos |
-
2013
- 2013-05-09 CN CN201380025338.6A patent/CN104302311A/zh active Pending
- 2013-05-09 MA MA37506A patent/MA37506B1/fr unknown
- 2013-05-09 WO PCT/US2013/040275 patent/WO2013173158A1/fr active Application Filing
- 2013-05-09 PE PE2014001980A patent/PE20142432A1/es not_active Application Discontinuation
- 2013-05-09 KR KR1020147031701A patent/KR20150002801A/ko not_active Application Discontinuation
- 2013-05-09 EP EP13724685.6A patent/EP2852398A1/fr not_active Withdrawn
- 2013-05-09 AU AU2013263188A patent/AU2013263188A1/en not_active Abandoned
- 2013-05-09 MX MX2014013913A patent/MX2014013913A/es unknown
- 2013-05-09 JP JP2015512695A patent/JP2015522539A/ja not_active Withdrawn
- 2013-05-09 CA CA2869320A patent/CA2869320A1/fr not_active Abandoned
- 2013-05-09 EA EA201491856A patent/EA201491856A1/ru unknown
- 2013-05-09 US US14/399,037 patent/US20150141335A1/en not_active Abandoned
- 2013-05-09 SG SG11201407655TA patent/SG11201407655TA/en unknown
- 2013-05-09 BR BR112014028413A patent/BR112014028413A2/pt not_active IP Right Cessation
-
2014
- 2014-09-30 TN TNP2014000409A patent/TN2014000409A1/fr unknown
- 2014-10-16 ZA ZA2014/07532A patent/ZA201407532B/en unknown
- 2014-10-22 CL CL2014002846A patent/CL2014002846A1/es unknown
- 2014-11-03 IL IL235482A patent/IL235482A0/en unknown
- 2014-11-14 CO CO14252512A patent/CO7131381A2/es unknown
- 2014-11-14 PH PH12014502537A patent/PH12014502537A1/en unknown
-
2015
- 2015-04-02 HK HK15103356.5A patent/HK1202800A1/xx unknown
Also Published As
Publication number | Publication date |
---|---|
WO2013173158A1 (fr) | 2013-11-21 |
KR20150002801A (ko) | 2015-01-07 |
ZA201407532B (en) | 2016-05-25 |
IL235482A0 (en) | 2014-12-31 |
HK1202800A1 (en) | 2015-10-09 |
EA201491856A1 (ru) | 2015-03-31 |
AU2013263188A1 (en) | 2014-10-16 |
SG11201407655TA (en) | 2014-12-30 |
EP2852398A1 (fr) | 2015-04-01 |
JP2015522539A (ja) | 2015-08-06 |
BR112014028413A2 (pt) | 2017-11-07 |
CO7131381A2 (es) | 2014-12-01 |
CL2014002846A1 (es) | 2015-01-30 |
PH12014502537A1 (en) | 2015-01-21 |
MX2014013913A (es) | 2015-02-17 |
PE20142432A1 (es) | 2015-01-22 |
CN104302311A (zh) | 2015-01-21 |
CA2869320A1 (fr) | 2013-11-21 |
TN2014000409A1 (en) | 2015-12-21 |
MA37506A1 (fr) | 2016-01-29 |
US20150141335A1 (en) | 2015-05-21 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
MA37506A1 (fr) | Utilisations thérapeutiques de protéines de facteur de croissance des fibroblastes 21 | |
EA201390060A1 (ru) | Аннелированные пиримидины и триазины и их применение для лечения и/или профилактики сердечно-сосудистых заболеваний | |
BR112015009924A2 (pt) | formulações de proteína imunoglobulina de domínio variável duplo estáveis | |
TR201910959T4 (tr) | Elektromanyetik radyasyonun insan irisine uygulanması. | |
EA202090516A3 (ru) | Бициклические гетероциклы в качестве ингибиторов fgfr | |
PE20150201A1 (es) | Proteinas del factor 21 de crecimiento del fibroblasto | |
EA201591616A1 (ru) | Трифторметил-замещенные аннелированные пиримидины и их применение | |
EA201791693A1 (ru) | Гетеродимерные иммуноглобулины | |
UY34721A (es) | Anticuerpos anti-hla-b*27 y usos de éstos. | |
GT201400057A (es) | 3-pirmidin-4-il-oxazolidin-2-onas como inhibidores de la idh mutante | |
EA201491811A1 (ru) | АНТИ-LgR5 АНТИТЕЛА И ИММУНОКОНЪЮГАТЫ | |
EA201590962A1 (ru) | Новые соединения | |
JO3357B1 (ar) | مركبات إيميدازوبيروليدينون | |
UY34602A (es) | ?Derivados de bencimidazolil- e imidazopiridinil-metilamina? | |
ECSP12012349A (es) | Agentes inductores de apoptosis contra el cáncer y de enfermedades inmunes y autoinmunes | |
ECSP12012348A (es) | Agentes inductores de apoptosis contra el cáncer y de enfermedades inmunes y autoinmunes | |
EA201491766A1 (ru) | Соединения для лечения спинальной мышечной атрофии | |
MA34521B1 (fr) | Polypeptides de relaxine modifiés et leurs utilisations | |
IN2014DN11201A (fr) | ||
EA201492040A1 (ru) | Бициклически замещённые урацилы и их применение | |
MD3355919T2 (ro) | Terapie combinată cu utilizarea inhibitorilor factorului de creștere și diferențiere uman 15 (GDF-15) și a blocanților punctelor de control imunitar | |
EA201490790A1 (ru) | Пептидные конъюгаты агониста рецептора гастрина и глюкагон подобного пептида 1 | |
EA201290744A1 (ru) | Имидазо[1,2-b][1,2,4]триазины в качестве c-met ингибиторов | |
FR3003173B1 (fr) | Substituts osseux greffes par des peptides mimetiques de la proteine humaine bmp-2. | |
EA201390955A1 (ru) | Слитый белок robo1-fc для применения в лечении гепатокарциномы |